IDRA News and Press, Idera Pharmaceuticals Inc. From 04/13/21

Shares of Idera Pharmaceuticals Inc. (NASDAQ:IDRA) traded today at $1.12, breaking its 52-week low. This new low was reached on approximately average trading volume as 6.3 million shares traded hands, while the average 30-day volume is approximately 5.5 million shares. Idera Pharmaceutic...

Gainers: Clovis Oncology (CLVS) +61%.ZK International (ZKIN) +47%.SuperCom (SPCB) +47%.SenesTech (SNES) +45%.AudioEye (AEYE) +29%.Super League Gaming (SLGG) +27%.Marker Therapeutics (MRKR) +26%.Hall of Fame Resort & Entertainment (HOFV) +25%.X4 Pharmaceuticals (XFOR) +...

Idera Pharmaceuticals ([[IDRA]] -63.7%) has faced multiple downgrades from Wall Street analysts following the announcement of results of its phase 3 ILLUMINATE-301 trial for tilsotolimod which failed to meet the primary endpoint with statistical significance.The analysts from H.C. Wainwr...

Shares of Idera Pharmaceuticals (NASDAQ: IDRA) were crashing 63.5% at 10:49 a.m. EDT on Friday. The plunge came after the company announced disappointing results Thursday from a late-stage study of tilsotolimod in combination with Bristol Myers Squibb 's Yervoy in treating advan...

Gainers: Clovis Oncology (CLVS) +43%, Marker Therapeutics (MRKR) +23%, Alector (ALEC) +17%, Aravive (ARAV) +14%, Ortho Clinical Diagnostics (OCDX) +8%.Losers: Idera Pharmaceuticals (IDRA) -62%, Praxis Precision Medicines (PRAX) -13%,  Acu...

Idera Pharmaceuticals (IDRA) is trading ~62.4% lower in the pre-market after yesterday’s post-market announcement of a setback in a phase 3 trial for Toll-like receptor 9 agonist tilsotolimod as a treatment for anti-PD1 refractory advanced melanoma.Today the analyst...

Idera Pharmaceuticals' (IDRA) tilsotolimod did not meet its primary endpoint in a phase 3 trial as a treatment for anti-PD1 refractory advanced melanoma.The phase 3 ILLUMINATE-301 trials was testing a combination of tilsotolimod and Bristol-Myers Squibb's (BMY) Yervoy (ipilimumab) vs. Yervoy ...

EXTON, Pa., March 18, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) today is announcing that ILLUMINATE-301, the Company’s pivotal registration trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients ...

Gainers: Second Sight Medical Products (EYES) +94%.OpGen (OPGN) +71%.Anchiano Therapeutics (ANCN) +66%.GameStop (GME) +44%.Jaguar Health (JAGX) +35%.Moxian (MOXC) +30%.Koss (KOSS) +30%.Idera Pharmaceuticals (IDRA) +28%.BSQUARE (BSQR) +25%.Greenwich LifeSciences (GLSI) +23%.Losers:&#...

Gainers: Second Sight Medical Products (EYES) +92%, OpGen (OPGN) +79%, Anchiano Therapeutics (ANCN) +64%, Jaguar Health (JAGX) +29%, Idera Pharmaceuticals (IDRA) +22%.Losers: Soleno Therapeutics (SLNO) -44%, AnaptysBio (ANAB) -34%, T...